Trial reportNature medicine2019
Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study.
5 registry-linked trialsOpen access · greenAbstract readRandomized Controlled Trial
In one paragraph
Trial report in Nature medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 1,251 papers, 6 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
1,251citing papers in PubMed, 6 pooled it
88.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Effects of 'Next Generation Beneficial Microbes', Akkermansia Muciniphila (AMF-01), on Long-term Improvements in Insulin Resistance in Otherwise Healthy Hyperglycaemic Adults
Effects of Very Low Calorie Ketogenic Diet on Microbiota, Adipose Tissue and Immunitary Regulation: Pilot Study on Patients with Metabolic Syndrome
The Effects of the Anti-inflammatory Microbe - Pasteurized Akkermansia Muciniphila (PAM) on Symptoms of Somatic and Mental Stress in Healthcare Professionals
Role of the Gut Microbiome as Determinant of Depression in Multiple Sclerosis Subjects
Supplementation With a Next-Generation Synbiotic in Individuals With Overweight or Obesity: A Triple-Blinded Randomized Controlled Clinical Trial
Who cites it
1,251 citing papers in PubMed, 6 syntheses or guidelines pooled it, 2,147 citations in OpenAlex.
- The Gut Microbiota in Addiction Biology: A Systematic Review of Substance-Induced Dysbiosis and Gut-Brain Axis Alterations.Medical sciences (Basel, Switzerland) · 2026Pooled it
- Pooled it
- Heart-Gut Axis in Cardiometabolic Disease: Microbiome-Mediated Pathways Linking Metabolic Syndrome to Cardiovascular Risk.Medicina (Kaunas, Lithuania) · 2026Pooled it
- Fecal microbiota transplantation in obesity: a comprehensive overview from basic research to clinical application.Frontiers in microbiology · 2026Pooled it
- Meta-analysis of 22,710 human microbiome metagenomes defines an oral-to-gut microbial enrichment score and associations with host health and disease.Nature communications · 2025Pooled it
- Therapeutic potential of Akkermansia muciniphila in non-alcoholic fatty liver disease: a systematic review.BMC gastroenterology · 2025Pooled it
- Effect of pasteurizedGut microbes · 2026Trial
- Weight Loss and Omega-3 Supplementation Modulate the Microbiome in Women with Increased Breast Cancer Risk.Cancer prevention research (Philadelphia, Pa.) · 2026Trial
- Pasteurized Akkermansia muciniphila MucNature medicine · 2026Trial
- Trial
- Trial
- Rethinking probiotics: breaking theGut microbes · 2026Review
- Gut-derived bacterial extracellular vesicles: the microbial dark matter contributing to host inflammation and cardiometabolic disease.Gut microbes · 2026Review
- Article
- Dysregulated eating behaviour and microbiota-based interventions targeting eating disorders and food addiction.Gut microbes · 2026Review
- A novel bile salt hydrolase-producingGut microbes · 2026Article
- Article
- Article
- Article
- Gut‑liver‑kidney axis: A systems biology framework for understanding and treating chronic kidney disease (Review).International journal of molecular medicine · 2026Review
1,191 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
16 authors at 5 institutions in 3 countries.
Clara Depommier *Metabolism and Nutrition Research Group, Louvain Drug Research Institute, WELBIO, Walloon Excellence in Life Sciences and BIOtechnology, UCLouvain, Université catholique de Louvain, Brussels, Belgium.
Amandine Everard *Metabolism and Nutrition Research Group, Louvain Drug Research Institute, WELBIO, Walloon Excellence in Life Sciences and BIOtechnology, UCLouvain, Université catholique de Louvain, Brussels, Belgium.
Céline DruartMetabolism and Nutrition Research Group, Louvain Drug Research Institute, WELBIO, Walloon Excellence in Life Sciences and BIOtechnology, UCLouvain, Université catholique de Louvain, Brussels, Belgium.
Hubert PlovierMetabolism and Nutrition Research Group, Louvain Drug Research Institute, WELBIO, Walloon Excellence in Life Sciences and BIOtechnology, UCLouvain, Université catholique de Louvain, Brussels, Belgium.
Matthias Van HulMetabolism and Nutrition Research Group, Louvain Drug Research Institute, WELBIO, Walloon Excellence in Life Sciences and BIOtechnology, UCLouvain, Université catholique de Louvain, Brussels, Belgium.
Sara Vieira-SilvaLaboratory of Molecular Bacteriology-Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-4616-7602
Gwen FalonyLaboratory of Molecular Bacteriology-Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium.
Jeroen RaesLaboratory of Molecular Bacteriology-Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium.
Dominique MaiterPôle EDIN, Institut de Recherches Expérimentales et Cliniques, UCLouvain, Université catholique de Louvain, Louvain-la-Neuve, Belgium.
Nathalie M DelzenneMetabolism and Nutrition Research Group, Louvain Drug Research Institute, UCLouvain, Université catholique de Louvain, Brussels, Belgium.
Marie de BarsyPôle EDIN, Institut de Recherches Expérimentales et Cliniques, UCLouvain, Université catholique de Louvain, Louvain-la-Neuve, Belgium.
Audrey LoumayePôle EDIN, Institut de Recherches Expérimentales et Cliniques, UCLouvain, Université catholique de Louvain, Louvain-la-Neuve, Belgium.
Michel P HermansPôle EDIN, Institut de Recherches Expérimentales et Cliniques, UCLouvain, Université catholique de Louvain, Louvain-la-Neuve, Belgium.
Jean-Paul ThissenPôle EDIN, Institut de Recherches Expérimentales et Cliniques, UCLouvain, Université catholique de Louvain, Louvain-la-Neuve, Belgium.
Willem M de VosLaboratory of Microbiology, Wageningen University, Wageningen, the Netherlands.ORCID http://orcid.org/0000-0002-0273-3166
Patrice D CaniMetabolism and Nutrition Research Group, Louvain Drug Research Institute, WELBIO, Walloon Excellence in Life Sciences and BIOtechnology, UCLouvain, Université catholique de Louvain, Brussels, Belgium. Patrice.cani@uclouvain.be.ORCID http://orcid.org/0000-0003-2040-2448
Walloon Excellence in Lifesciences and Biotechnology · BECliniques Universitaires Saint-Luc · BERega Institute for Medical Research · BEUCLouvain · BEUniversity of Helsinki · FI
Funding
European Research Council 336452
Abstract
Metabolic syndrome is characterized by a constellation of comorbidities that predispose individuals to an increased risk of developing cardiovascular pathologies as well as type 2 diabetes mellitus
Indexed as
Dietary SupplementsVerrucomicrobiaAdultAgedDouble-Blind MethodFecesGastrointestinal MicrobiomeHumansInsulin ResistanceMiddle AgedObesityOverweightPilot Projects
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT05114018ClinicalTrials.gov
NCT05275608ClinicalTrials.gov
NCT05738746ClinicalTrials.gov
NCT05808101ClinicalTrials.gov
NCT06213480ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.